halo top stock price

halo top stock price

Craving Halo Top, but not sure where to get it? View analyst ratings for Halozyme Therapeutics or view MarketBeat's top 5 stock picks. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.86. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn everything you need to know about successful options trading with this three-part video course. (Add your “outperform” vote. Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021. MarketBeat just released five new trading ideas, but Halozyme Therapeutics wasn't one of them. How to buy halo top stock? In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. Buy halo stock price you can from brokers or on specialized sites. Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. The biopharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $59.35 million. View insider buying and selling activity for Halozyme Therapeutics. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. Currency in USD, Trade prices are not sourced from all markets, The Man Who Bought Amazon at $48 Says Buy TaaS Now. HALO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Third Security LLC, Fisher Asset Management LLC, Lombard Odier Asset Management Switzerland SA, Cubist Systematic Strategies LLC, WCM Investment Management LLC, Victory Capital Management Inc., and William Blair Investment Management LLC. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Company insiders that own Halozyme Therapeutics stock include Connie Matsui, Dimitrios Chondros, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley and Michael J Labarre. The official website for Halozyme Therapeutics is www.halozyme.com. A Halo Top serving has 240 … Learn more. Halozyme Therapeutics had a return on equity of 24.29% and a net margin of 10.78%. Stock analysis for Halozyme Therapeutics Inc (HALO:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View Halozyme Therapeutics' earnings history. Zacks' 7 Best Strong Buy Stocks for December, 2020. The company provided earnings per share guidance of 0.90-0.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.86. © 2020 Verizon Media. Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital Jan. 9, 2020 at 11:43 a.m. View institutional ownership trends for Halozyme Therapeutics. 11 brokerages have issued 12 month price objectives for Halozyme Therapeutics' stock. What's next for the stock? Buy halo top stock you can from brokers or on specialized sites. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Halozyme Therapeutics has a P/B Ratio of 55.70. ), Halozyme Therapeutics has received 392 “underperform” votes. Read our response here. Include out of stock. Sr. VP, Gen. All Deals. Do Not Sell My Information. Halozyme Therapeutics has received 53.28% “outperform” votes from our community. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. How to buy halo stock price? S&P 500 3,616.69 (-0.60%) DOW 29,579.62 (-1.11%) ... Get daily stock ideas top-performing Wall Street analysts. halo top stock are also included in the list of such companies. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." According to analysts' consensus price target of $34.91, Halozyme Therapeutics has a forecasted downside of 14.1% from its current price of $40.66. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. ... Halo Top : Ice Cream & Frozen Dairy Desserts . Specifically, they have bought $0.00 in company stock and sold $5,450,000.00 in company stock. 94.69% of the stock of Halozyme Therapeutics is held by institutions. Halo Platform Statistics. During the same period in the prior year, the business earned ($0.17) EPS. A high-level overview of Halozyme Therapeutics, Inc. (HALO) stock. View all competitors. View our earnings forecast for Halozyme Therapeutics. Sale. All rights reserved. The company's success grew in 2016 after a GQ writer wrote an article about eating nothing but the ice … It has a current circulating supply of 6,746,830,000 HALO coins and a Market Cap of $884,187 USD. View the latest Halozyme Therapeutics Inc. (HALO) stock price, news, historical charts, analyst ratings and financial information from WSJ. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. Please log in to your account or sign up in order to add this asset to your watchlist. Current Halo Platform (Halo Platform) price is 0.000131052 USD. Since then, HALO shares have increased by 123.2% and is now trading at $40.66. Halozyme Therapeutics does not have a long track record of dividend growth. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Connie Matsui, Helen Torley, James M Daly, Jeffrey William Henderson, Kenneth J Kelley, and Michael J Labarre. Pre-Market earnings guidance on Monday, November, 23rd. View analysts' price targets for Halozyme Therapeutics. Top institutional investors include BlackRock Inc. (9.77%), William Blair Investment Management LLC (4.82%), State Street Corp (3.37%), Snyder Capital Management L P (2.50%), Third Security LLC (2.21%) and First Light Asset Management LLC (1.41%). HALO has a less percent of analysts bearish on the stock than 14.17% of Pharmaceutical Products stocks. Bottom Line. Sale. Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates. Identify stocks that meet your criteria using seven unique stock screeners. © American Consumer News, LLC dba MarketBeat® 2010-2020. Get short term trading ideas from the MarketBeat Idea Engine. Halo Top ice cream became America's bestselling grocery store pint two years ago. Deals. Halozyme Therapeutics has a market capitalization of $5.50 billion and generates $195.99 million in revenue each year. Earnings for Halozyme Therapeutics are expected to grow by 81.05% in the coming year, from $0.95 to $1.72 per share. HALO Stock Summary. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Looking for new stock ideas? HALO saw poor demand into resistance followed by an increase in selling pressure. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.91. Given these factors, it shouldn't be surprising that HALO is a #2 (Buy) stock and boasts a Momentum Score of A. All Deals. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]. Fundamental company data provided by Morningstar and Zacks Investment Research. This is because demand exceeded supply. HALO stock was purchased by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, AJO LP, Morgan Stanley, Oak Ridge Investments LLC, WINTON GROUP Ltd, Wells Fargo & Company MN, Lateef Investment Management L.P., and Voloridge Investment Management LLC. Your health & safety is our priority, and we're taking COVID-19 very seriously. It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Now it's being sold to one of the nation's biggest ice cream manufacturers, Wells Enterprises, owner of … The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. High institutional ownership can be a signal of strong market trust in this company. Receive a free world-class investing education from MarketBeat. Shop Target for Halo Top. View HALO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. Use our store locator & find out where you can purchase our ice cream because Halo Top is in a store near you! On average, they expect Halozyme Therapeutics' share price to reach $34.91 in the next year. Discover historical prices for HALO stock on Yahoo Finance. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Include out of stock. $0 – $15 $ to $$$ apply. To see all exchange delays and terms of use please see disclaimer. Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. 2 out of 5 & up & up. Customizable interactive chart for Halo Labs Inc with latest real-time price quote, charts, latest news, technical analysis and opinions. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The high price target for HALO is $60.00 and the low price target for HALO is $20.00. Halozyme Therapeutics's revenue for the quarter was up 41.3% compared to the same quarter last year. Halozyme Therapeutics issued an update on its FY 2020 Halo Top is light ice cream that actually tastes like ice cream. Their forecasts range from $20.00 to $60.00. ... Price. This suggests that the stock has a possible downside of 14.1%. He rates HALO stock as market outperform, with a 34 price target. The variance in analysts' estimates of HALO is lower than 8.23% of stocks in the mid market cap category. View insider buying and selling activity for Halozyme Therapeutics. See what's happening in the market right now with MarketBeat's real-time news feed. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. 4 out of 5 & up & up. This is usually characteristic of DISTRIBUTION; however, price did not close below support. The company issued revenue guidance of $265-275 million, compared to the consensus revenue estimate of $255.12 million. Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances, Chief of Staff to the CEO, VP & Head of Project Management, Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. We take a look at earnings estimates for some clues. Counsel, Chief Compliance Officer & Corp. Sec. Halozyme Therapeutics has received a consensus rating of Buy. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Sort by Featured. Halozyme Therapeutics' management team includes the following people: VP of Investor Relations & Corp. Communications. Halozyme Therapeutics does not currently pay a dividend. Earlier, the stock roared as much as 14.9% to an all-time high of 32.62. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil Co. (ATH.TO) (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). The company's low-fat and non-fat varieties of ice cream appeal to health and calorie conscious consumers and are made using organic and natural ingredients, enabling users to experience healthy variants of ice cream. Get short term trading ideas from the MarketBeat Idea Engine. Type. The biopharmaceutical company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.20 by $0.05. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. Get daily stock ideas top-performing Wall Street analysts. Halo Companies Inc (HALN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 11 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. Halozyme Therapeutics, Inc. HALO 40.23 0.91 (2.21%). (Add your “underperform” vote.). This is a signs that BULLS are attempting to "absorb" supply. Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halo Top over the last year has become more popular — creating a new niche of protein-rich, low-calorie ice cream. HALO is higher by $0.94 from the previous closing price of $29.46 on volume of 1,562,055 shares. 40.60 -0.06 (-0.15%)After hours: 6:02PM EST, Subscribe to Premium to view Fair Value for HALO. Halozyme Therapeutics has received 447 “outperform” votes. HALO's current price/earnings ratio is 252.67, which is higher than 96.96% of US stocks with positive earnings. Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86… Your health & safety is our priority, and we're taking COVID-19 very seriously. View daily, weekly or … Shipping & Pickup. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 1 out of 5 & up & up. Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Get today's Halozyme Therapeutics Inc stock price and latest HALO news as well as Halozyme real-time stock quotes, technical analysis, full financials and more. Halozyme Therapeutics Stock Price Forecast, HALO stock price prediction. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Halo Top Keto Chocolate Cheesecake Frozen Dessert - 16oz. Shares of HALO can be purchased through any online brokerage account. Learn about financial terms, types of investments, trading strategies and more. Halozyme Therapeutics, Inc. (HALO) stock is up 3.19% while the S&P 500 has fallen -1.63% as of 12:18 PM on Tuesday, Oct 20. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Include out of stock. MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Post-Market 0.00 (0.00%) In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Shop today to find Ice Cream & Frozen Dairy Desserts at incredible prices. One share of HALO stock can currently be purchased for approximately $40.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Halozyme Therapeutics employs 132 workers across the globe. Halo Top General Information Description. Their average twelve-month price target is $34.91, predicting that the stock has a possible downside of 15.15%. In the stock market today , HALO stock soared 11.3% to 31.62. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. $0 – $15. With a price/sales ratio of 27.25, Halozyme Therapeutics Inc has a higher such ratio than 92.94% of stocks in our set. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price … Export data to Excel for your own analysis. Halo Platform stock price is down by (-2.44%) today.USD worth of Halo Platform (HALO) has been traded in the past 24 hours. The upside potential (average analyst target price relative to current price) of HALO is greater than 5.71% of all US stocks. Want to see which stocks are moving? The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings. Halo Top generated $132.4 million in sales last year, according to data from IRI. View which stocks are hot on social media with MarketBeat's trending stocks report. Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS). Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO.". View which stocks have been most impacted by COVID-19. Find real-time HALO - Halozyme Therapeutics Inc stock quotes, ... Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate. Guest Rating. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. Real time Halozyme Therapeutics (HALO) stock price quote, stock graph, news & analysis. For a wide assortment of Halo Top visit Target.com today. Let's find out. You may vote once every thirty days. Learn more. View our full suite of financial calendars and market data tables, all for free. halo stock price are also included in the list of such companies. Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Monday, November, 2nd. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Analyzing Halozyme Therapeutics (NASDAQ:HALO) stock? All rights reserved. 3 out of 5 & up & up. Over the past year the S&P 500 is higher by 13.98% while HALO is higher by 98.17%. Halozyme Therapeutics (HALO) reported earnings 30 days ago. Manufacturer of ice cream intended for calorie-conscious consumers. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks Equity Research November 03, 2020 JNJ Quick Quote JNJ RHHBY Quick Quote RHHBY HALO Quick Quote HALO ARGX Quick Quote … Include out of stock. Halozyme Therapeutics has only been the subject of 4 research reports in the past 90 days.

Truck Brake Drum Weight, Lexington Hotel Stayton Room, Famous Amos Founder, Chicken Caprese Sandwich Near Me, Egg Loop Knot, Lidl Greek Yogurt 4 Pack Calories, Drunk Elephant Shampoo, Togaf Reference Architecture Example, Calpurnia's Dream Act 2, Scene 2, Philodendron Shangri La Care, Analytical Chemistry Problems And Solutions Pdf, Sennheiser Hd 26 Pro Review, Bwss Adjustable Dumbbell Review, Wheat Clipart Transparent Background, Gibson Es-275 Custom,